Adult Vaccines Market Size to Hit USD 50.39 Billion by 2035

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Adult Vaccines Market

5.1. COVID-19 Landscape: Adult Vaccines Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Adult Vaccines Market, By Vaccine Type

8.1. Adult Vaccines Market Revenue and Volume Forecast, by Vaccine Type

8.1.1. Influenza Vaccines

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Pneumococcal Vaccines

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Hepatitis Vaccines

8.1.3.1. Market Revenue and Volume Forecast

8.1.4. HPV Vaccines

8.1.4.1. Market Revenue and Volume Forecast

8.1.5. Zoster/Shingles Vaccines

8.1.5.1. Market Revenue and Volume Forecast

8.1.6. Meningococcal Vaccines

8.1.6.1. Market Revenue and Volume Forecast

8.1.7. Others

8.1.7.1. Market Revenue and Volume Forecast

Chapter 9. Global Adult Vaccines Market, By Application

9.1. Adult Vaccines Market Revenue and Volume Forecast, by Application

9.1.1. Routine Immunization

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Travel Vaccines

9.1.2.1. Market Revenue and Volume Forecast

9.1.3. Occupational/Other Immunization

9.1.3.1. Market Revenue and Volume Forecast

9.1.4. Outbreak/Response Vaccination

9.1.4.1. Market Revenue and Volume Forecast

Chapter 10. Global Adult Vaccines Market, By Distribution Channel

10.1. Adult Vaccines Market Revenue and Volume Forecast, by Distribution Channel

10.1.1. Hospitals & Clinics

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Pharmacies/ Retail Pharmacies

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. Government Suppliers

10.1.3.1. Market Revenue and Volume Forecast

10.1.4. Others

10.1.4.1. Market Revenue and Volume Forecast

Chapter 11. Global Adult Vaccines Market, By Age Group

11.1. Adult Vaccines Market Revenue and Volume Forecast, by Age Group

11.1.1. 18–30 years

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. 31–50 years

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. 51–65 years

11.1.3.1. Market Revenue and Volume Forecast

11.1.4. Above 65 years

11.1.4.1. Market Revenue and Volume Forecast

Chapter 12. Global Adult Vaccines Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Volume Forecast, by Vaccine Type

12.1.2. Market Revenue and Volume Forecast, by Application

12.1.3. Market Revenue and Volume Forecast, by Distribution Channel

12.1.4. Market Revenue and Volume Forecast, by Age Group

12.1.5. U.S.

12.1.5.1. Market Revenue and Volume Forecast, by Vaccine Type

12.1.5.2. Market Revenue and Volume Forecast, by Application

12.1.5.3. Market Revenue and Volume Forecast, by Distribution Channel

12.1.5.4. Market Revenue and Volume Forecast, by Age Group

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Volume Forecast, by Vaccine Type

12.1.6.2. Market Revenue and Volume Forecast, by Application

12.1.6.3. Market Revenue and Volume Forecast, by Distribution Channel

12.1.6.4. Market Revenue and Volume Forecast, by Age Group

12.2. Europe

12.2.1. Market Revenue and Volume Forecast, by Vaccine Type

12.2.2. Market Revenue and Volume Forecast, by Application

12.2.3. Market Revenue and Volume Forecast, by Distribution Channel

12.2.4. Market Revenue and Volume Forecast, by Age Group

12.2.5. UK

12.2.5.1. Market Revenue and Volume Forecast, by Vaccine Type

12.2.5.2. Market Revenue and Volume Forecast, by Application

12.2.5.3. Market Revenue and Volume Forecast, by Distribution Channel

12.2.5.4. Market Revenue and Volume Forecast, by Age Group

12.2.6. Germany

12.2.6.1. Market Revenue and Volume Forecast, by Vaccine Type

12.2.6.2. Market Revenue and Volume Forecast, by Application

12.2.6.3. Market Revenue and Volume Forecast, by Distribution Channel

12.2.6.4. Market Revenue and Volume Forecast, by Age Group

12.2.7. France

12.2.7.1. Market Revenue and Volume Forecast, by Vaccine Type

12.2.7.2. Market Revenue and Volume Forecast, by Application

12.2.7.3. Market Revenue and Volume Forecast, by Distribution Channel

12.2.7.4. Market Revenue and Volume Forecast, by Age Group

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Volume Forecast, by Vaccine Type

12.2.8.2. Market Revenue and Volume Forecast, by Application

12.2.8.3. Market Revenue and Volume Forecast, by Distribution Channel

12.2.8.4. Market Revenue and Volume Forecast, by Age Group

12.3. APAC

12.3.1. Market Revenue and Volume Forecast, by Vaccine Type

12.3.2. Market Revenue and Volume Forecast, by Application

12.3.3. Market Revenue and Volume Forecast, by Distribution Channel

12.3.4. Market Revenue and Volume Forecast, by Age Group

12.3.5. India

12.3.5.1. Market Revenue and Volume Forecast, by Vaccine Type

12.3.5.2. Market Revenue and Volume Forecast, by Application

12.3.5.3. Market Revenue and Volume Forecast, by Distribution Channel

12.3.5.4. Market Revenue and Volume Forecast, by Age Group

12.3.6. China

12.3.6.1. Market Revenue and Volume Forecast, by Vaccine Type

12.3.6.2. Market Revenue and Volume Forecast, by Application

12.3.6.3. Market Revenue and Volume Forecast, by Distribution Channel

12.3.6.4. Market Revenue and Volume Forecast, by Age Group

12.3.7. Japan

12.3.7.1. Market Revenue and Volume Forecast, by Vaccine Type

12.3.7.2. Market Revenue and Volume Forecast, by Application

12.3.7.3. Market Revenue and Volume Forecast, by Distribution Channel

12.3.7.4. Market Revenue and Volume Forecast, by Age Group

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Volume Forecast, by Vaccine Type

12.3.8.2. Market Revenue and Volume Forecast, by Application

12.3.8.3. Market Revenue and Volume Forecast, by Distribution Channel

12.3.8.4. Market Revenue and Volume Forecast, by Age Group

12.4. MEA

12.4.1. Market Revenue and Volume Forecast, by Vaccine Type

12.4.2. Market Revenue and Volume Forecast, by Application

12.4.3. Market Revenue and Volume Forecast, by Distribution Channel

12.4.4. Market Revenue and Volume Forecast, by Age Group

12.4.5. GCC

12.4.5.1. Market Revenue and Volume Forecast, by Vaccine Type

12.4.5.2. Market Revenue and Volume Forecast, by Application

12.4.5.3. Market Revenue and Volume Forecast, by Distribution Channel

12.4.5.4. Market Revenue and Volume Forecast, by Age Group

12.4.6. North Africa

12.4.6.1. Market Revenue and Volume Forecast, by Vaccine Type

12.4.6.2. Market Revenue and Volume Forecast, by Application

12.4.6.3. Market Revenue and Volume Forecast, by Distribution Channel

12.4.6.4. Market Revenue and Volume Forecast, by Age Group

12.4.7. South Africa

12.4.7.1. Market Revenue and Volume Forecast, by Vaccine Type

12.4.7.2. Market Revenue and Volume Forecast, by Application

12.4.7.3. Market Revenue and Volume Forecast, by Distribution Channel

12.4.7.4. Market Revenue and Volume Forecast, by Age Group

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Volume Forecast, by Vaccine Type

12.4.8.2. Market Revenue and Volume Forecast, by Application

12.4.8.3. Market Revenue and Volume Forecast, by Distribution Channel

12.4.8.4. Market Revenue and Volume Forecast, by Age Group

12.5. Latin America

12.5.1. Market Revenue and Volume Forecast, by Vaccine Type

12.5.2. Market Revenue and Volume Forecast, by Application

12.5.3. Market Revenue and Volume Forecast, by Distribution Channel

12.5.4. Market Revenue and Volume Forecast, by Age Group

12.5.5. Brazil

12.5.5.1. Market Revenue and Volume Forecast, by Vaccine Type

12.5.5.2. Market Revenue and Volume Forecast, by Application

12.5.5.3. Market Revenue and Volume Forecast, by Distribution Channel

12.5.5.4. Market Revenue and Volume Forecast, by Age Group

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Volume Forecast, by Vaccine Type

12.5.6.2. Market Revenue and Volume Forecast, by Application

12.5.6.3. Market Revenue and Volume Forecast, by Distribution Channel

12.5.6.4. Market Revenue and Volume Forecast, by Age Group

Chapter 13. Company Profiles

13.1. GlaxoSmithKline plc (GSK)

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial PerVaccine Typeance

13.1.4. Recent Initiatives

13.2. Sanofi S.A.

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial PerVaccine Typeance

13.2.4. Recent Initiatives

13.3. Merck & Co., Inc.

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial PerVaccine Typeance

13.3.4. Recent Initiatives

13.4. Pfizer Inc.

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial PerVaccine Typeance

13.4.4. Recent Initiatives

13.5. AstraZeneca plc

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial PerVaccine Typeance

13.5.4. Recent Initiatives

13.6. Moderna, Inc.

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial PerVaccine Typeance

13.6.4. Recent Initiatives

13.7. BioNTech SE

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial PerVaccine Typeance

13.7.4. Recent Initiatives

13.8. Serum Institute of India Pvt. Ltd.

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial PerVaccine Typeance

13.8.4. Recent Initiatives

13.9. Emergent BioSolutions Inc.

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial PerVaccine Typeance

13.9.4. Recent Initiatives

13.10. Sinovac Biotech Ltd.

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial PerVaccine Typeance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

Answer : The adult vaccines market size is expected to increase from USD 19.97 billion in 2025 to USD 50.39 billion by 2035.

Answer : The adult vaccines market is expected to grow at a compound annual growth rate (CAGR) of around 9.70% from 2026 to 2035.

Answer : The driving factors of the adult vaccines market are the increasing disease burden and growing focus on preventive healthcare.

Answer : North America region will lead the global adult vaccines market during the forecast period 2026 to 2035.